It has been reported that intratumoral administration of low doses CpG and OX40 agonistic antibody triggered tumor-specific T cell response, suppressed the growth of the injected, as well as the untreated abscopal tumors and achieved significantly prolonged survival [30]. Here, TNFRSF4 is linked to neoplasm.